Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that is differentially expressed in resting and activated B cells. FOXP1 expression has been demonstrated in a subset of diffuse large B-cell lymphomas (DLBCLs) and is more common in the nongerminal center (non-GC), activated B-cell type; however, its prognostic significance is uncertain. We analyzed presentation lymph nodes from 126 patients with nodal DLBCL, previously classified according to GC and BCL2 status, for FOXP1 protein expression using standard immunocytochemistry. Uniform high FOXP1 expression was demonstrated in 23 of 126 patients with DLBCL. This high level of expression was almost exclusively confined to patients who lacked the GC phenotype, who expressed MUM-1 and BCL2 in the absence of t(14; 18), and who were identified as a subgroup of patients with particularly poor outcomes in a group with already poor prognoses. The data presented suggest that high FOXP1 expression is an independent prognostic factor in DLBCL.

Original publication

DOI

10.1182/blood-2004-03-1209

Type

Journal article

Journal

Blood

Publication Date

01/11/2004

Volume

104

Pages

2933 - 2935

Keywords

Biomarkers, Tumor, Chi-Square Distribution, DNA-Binding Proteins, Forkhead Transcription Factors, Gene Expression Regulation, Neoplastic, Humans, Interferon Regulatory Factors, Lymph Nodes, Lymphoma, Large B-Cell, Diffuse, Prognosis, Proto-Oncogene Proteins c-bcl-2, Repressor Proteins, Survival Analysis, Transcription Factors